[Skip To Content]
[Website of the National Cancer Institute's Technology Transfer Center.  Partnering with Industry for Improved Public Health.]
  • Home
  • Collaborative Opportunities
  • Standard Forms and Agreements
  • Technology Transfer Training
  • Resources
  • Intellectual Property

Therapeutics To Treat Ocular Diseases

Keywords: Therapeutics, eye disease, macular degeneration

The National Eye Institute's Section on Epithelial and Retinal Physiology and Disease (SERPD) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize therapeutics for ocular diseases caused by accumulation of sub-retinal fluid.

The accumulation of subretinal fluid is associated with retinal injury, post-surgical complications, and numerous adverse ocular conditions, including chronic macular edema, age related macular degeneration, and diabetic retinopathy.  Aberrant proliferation and migration of retinal pigment epithelial (RPE) cells is also associated with these conditions.  Interferon gamma (IFN-gamma) has been implicated in the pathogenesis of a number of intraocular inflammatory or infectious diseases. 

NIH inventors have shown that interferon-gamma (IFN-gamma) can significantly inhibit abnormal RPE proliferation and migration and can be used to remove subretinal fluid.  The application of IFN-gamma may be by external application (e.g. eye drops or ointments) or by subretinal injection.  This invention may be used to treat the debilitating complications of age-related macular degeneration, chronic macular edema, diabetic retinopathy, retinal detachment, glaucoma, or other diseases that are associated with abnormal fluid accumulation in the subretinal space.  Additionally, the invention describes methods for treating decreases in visual acuity associated with this type of fluid accumulation.

Further R&D Needed:

  • Pre-clinical trials
  • Phase I clinical trial
R&D Status:  Preclinical in vitro and animal model studies are in progress.

IP Status:  U. S. Provisional Application No. 61/089,157 filed 15 Aug 2008

Value Proposition:
  • Novel method to remove subretinal fluid to inhibit abnormal RPE proliferation and migration
  • Potential to treat numerous ocular diseases and decreases in visual acuity by either external application or injection
  • Ability to reduce retinal injury and post-surgical complications associated with accumulation of subretinal fluid

Contact Information:
Alan Hubbs, Ph.D.
NCI Technology Transfer Center
Tel.: 301-594-4263
Email: hubbsa@mail.nih.gov

Please reference advertisement # 771

Revised 12/23/2008


TTC maintains an e-mail service to notify you of new Collaborative Opportunities. If you would like to receive these emails, please sign up below. If you'd like to unsubscribe you can use this form as well.

Page Last Updated: 12-17-2008